Glenmark Announces The Discovery Of A Novel Chemical Entity ‘GRC 17536′, A TRPA1 Receptor Antagonist, A Potential First-in-Class Molecule Globally
Glenmark Pharmaceuticals announced the discovery of a Novel Chemical Entity(NCE) 'GRC 17536'. The new NCE program is targeting TRPA1 receptor antagonists for pain and respiratory disorders...
(more...)
(more...)